Status | Study |
Recruiting |
Study Name: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Condition: Childhood Choroid Plexus Tumor Childhood Ependymoblastoma Date: 2014-09-30 Interventions: Drug: palbociclib isethionate |
Withdrawn |
Study Name: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Condition: Acoustic Schwannoma Adult Anaplastic Astrocytoma Adult Ana Date: 2014-07-16 Interventions: Radiation: gallium Ga 68-edotreotide |
Active, not recruiting |
Study Name: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Condition: Childhood Choroid Plexus Tumor Childhood Medulloblastoma Date: 2013-11-12 Interventions: Biological: filgrastim Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on |
Active, not recruiting |
Study Name: Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Condition: Central Nervous System Tumor, Pediatric Chemotherapy-induced Nausea and Vomiting Date: 2011-04-29 Interventions: Procedure: Real Acupressure Band |
Completed |
Study Name: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Condition: Brain and Central Nervous System Tumors Lymphoma Lymphopro Date: 2011-01-07 Interventions: Drug: imetelstat sodium Other: laboratory |
Active, not recruiting |
Study Name: Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Condition: Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Date: 2010-10-07 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Condition: Brain and Central Nervous System Tumors Date: 2010-07-07 Interventions: Drug: VEGF inhibitor PTC299 This is a dose escalation study. Study participants will receive .6 or 1.2 m |
Terminated |
Study Name: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Condition: Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Date: 2010-03-16 Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097 |
Completed |
Study Name: Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Condition: Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Date: 2010-02-25 Interventions: Drug: vorinostat Other Names: |
Completed |
Study Name: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Condition: Childhood Burkitt Lymphoma Childhood Central Nervous System Choriocarcinoma Date: 2009-10-10 Interventions: Drug: vorinostat Given orally |